Aclaris Therapeutics ACRS Drug Candidate Bosakitug — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's drug candidate bosakitug — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's drug candidate bosakitug — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate bosakitug — research and development project spend of $3.14M in Q1 2026.
- How has Aclaris Therapeutics's drug candidate bosakitug — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug candidate bosakitug — research and development project spend decreased by 7.2% year-over-year, from $3.38M to $3.14M.
- What does drug candidate bosakitug — research and development project spend mean?
- This metric represents the total direct costs and allocated resources dedicated to the research and development activities for a specific drug candidate within the company's clinical pipeline. It captures the financial commitment required to advance the asset through preclinical studies, clinical trials, and regulatory milestones. Monitoring this spend provides insight into the company's capital allocation strategy and the progression of its therapeutic portfolio.